TGA issues alert after person was hospitalised after believing they were taking experimental weight loss drug retatrutide
-
Get our breaking news email, free app or daily news podcast
A patient who tore their oesophagus after taking a counterfeit version of an experimental weight loss drug has prompted Australia’s medicines regulator to warn of serious risks of such products.
The concern relates to retatrutide, a type of drug known as a peptide. Retatrutide has not been approved by the Therapeutic Goods Administration (TGA) or regulators overseas, and it cannot be legally prescribed or sold in Australia.
The post Peptide user tore oesophagus after using counterfeit product, Australian regulator warns appeared first on World news | The Guardian.